Illumina's CEO Promises Growth By 2027, Because Patience Is A Strategy
Jacob Thaysen, Illumina's fearless captain navigating the turbulent biotech seas, insists they're still on course for a modest 'high single-digit revenue growth' by the distant shores of 2027. Despite unexpected headwinds—likely a fancy euphemism for market chaos, supply chain mayhem, or maybe his coffee machine breaking—the CEO remains optimistic. Illumina, known for turning DNA into some kind of money magic, apparently believes five more years of slow growth is an acceptable life strategy. It's 2024, investors might just want to pop some popcorn and enjoy the slowest rollercoaster ride in corporate history.
Share the Story
(1 of 3)Illumina’s CEO is basically telling investors, 'Hang tight, it’s a glacier-speed race to glory by 2027,' because nothing screams excitement like three years to reach what a startup might pull off in six months.
Who needs quarterly fireworks when you can watch Illumina’s revenue growth crawl at a snail’s pace through 2027? CEO must think investors love suspenseful slow burns.
Illumina’s strategy: convince Wall Street that waiting for 'high single-digit growth' five years from now is a thrilling binge-watch, not a patience test.
Source: Statnews | Published: 8/26/2025 | Author: Jonathan Wosen
More Articles in Business
Trump Declares Ceasefire Dead But Keeps Talking Anyway, Because Logic
Tesla Laughs as Other Automakers Slam Doors on EVs, Ride Gas Price Rollercoaster
NYC Hotel’s Kitchen Uses 2,000 Eggs Weekly to Feed Masses, Not Chickens
MrBeast's Candy Empire Faces Sugar Crash, Now Selling Ethics Instead of Joy
Man Trades Time For Money Then Tries To Retire Before Age 30, Shockingly
LinkedIn Now 40% AI Slop, Humans Banned for Spelling Mistakes
